The increase in plasma PAI-1 associated with insulin resistance may be mediated by the presence of hepatic steatosis

Atherosclerosis

Volumn 208, Issue 1, 2010, Pages 240-245

  Ardigò, Diego ^a   Franzini, Laura ^a   Valtueña, Silvia ^a   Numeroso, Filippo ^a   Piatti, Pier Marco ^b   Monti, Lucilla ^b   Reaven, Gerald M ^c   Zavaroni, Ivana ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alcohol intake; Hyperinsulinemia; Insulin resistance; Liver steatosis; Plasminogen activator inhibitor 1

Indexed keywords

AMINOTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; ALCOHOL CONSUMPTION; ALCOHOLIC FATTY LIVER; ARTICLE; CLINICAL FEATURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRINKING BEHAVIOR; FATTY LIVER; FEMALE; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; ULTRASOUND; VOLUNTEER;

CROSS-SECTIONAL STUDIES; FATTY LIVER; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1;

EID: 73449109471     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.06.026     Document Type: Article

References (29)

1. Juhan-Vague I., Pyke S.D., Alessi M.C., et al. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 94 9 (1996) 2057-2063
2. Thogersen A.M., Jansson J.H., Boman K., et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 98 (1998) 2241-2247
3. Scarabin P.Y., Aillaud M.F., Amoyel P., et al. Association of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction: the PRIME Study. Thromb Haemost 80 (1998) 749-756
4. Kohler H.P., and Grant P.J. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Eng J Med 342 (2000) 1792-1801
5. Abbasi F., McLaughlin T., Lamendola C., et al. Comparison of plasminogen activator inhibitor-1 concentration in insulin-resistant versus insulin-sensitive healthy women. Arterioscler Thromb Vasc Biol 1 11 (1999) 2818-2821
6. Reaven G.M. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease. Panminerva Med 47 4 (2005) 201-210
7. Kooistra T., Bosma P., Tons H., et al. Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb Haemost 62 (1989) 723-728
8. Leiper K., Croll A., Booth N.A., et al. Tissue plasminogen activator, plasminogen activator inhibitors, and activator-inhibitor complex in liver disease. J Clin Pathol 47 3 (1994) 214-217
9. Inoue K., Sugawara Y., Kubota K., Takayama T., and Makuuchi M. Induction of type 1 plasminogen activator inhibitor in human liver ischemia and reperfusion. J Hepatol 33 3 (2000) 407-414
10. Alessi M.C., Bastelica D., Mavri A., et al. Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation. Arterioscler Thromb Vasc Biol 23 7 (2003) 1262-1268
11. Marchesini G., Brizi M., Morselli-Labate A.M., et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 107 5 (1999) 450-455
12. Zavaroni I., Bonora E., Pagliara M., et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med 320 (1989) 702-706
13. Zavaroni I., Bonini L., Gasparini P., et al. Hyperinsulinemia in a normal population as a predictor of non-insulin-dependent diabetes mellitus, hypertension, and coronary heart disease: the Barilla factory revisited. Metabolism 48 (1999) 989-994
14. Ardigo D., Numeroso F., Valtuena S., et al. Hyperinsulinemia predicts hepatic fat content in healthy individuals with normal transaminase concentrations. Metabolism 54 12 (2005) 1566-1570
15. Valtuena S., Numeroso F., Ardigo D., et al. Relationship among leptin, insulin, body composition and liver steatosis in non-diabetic moderate drinkers with normal transaminase levels. Eur J Endocrinol 153 2 (2005) 283-290
16. Saverymuttu S.H., Joseph A.E.A., and Maxwell J.D. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J 292 (1986) 13-15
17. Alessi M.C., Juhan-Vague I., Kooistra T., Declerck P.J., and Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb Haemost 60 (1988) 491-494
18. Kooistra T., Bosma P.J., Tons H.A., et al. Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb Haemost 62 (1989) 723-728
19. Bastard J.P., Bruckert E., Porquet D., et al. Evidence for a relationship between plasminogen activator inhibitor-1 and {gamma}-glutamyl transferase. Thromb Res 81 (1996) 271-275
20. Cigolini M., Targher G., Agostino G., et al. Liver steatosis and its relation to plasma haemostatic factors in apparently healthy men: role of the metabolic syndrome. Thromb Haemost 76 (1996) 69-73
21. Dimova E.Y., and Kietzmann T. Metabolic, hormonal and environmental regulation of plasminogen activator inhibitor-1 (PAI-1) expression: lessons from the liver. Thromb Haemost 100 6 (2008) 992-1006
22. Dimova E.Y., and Kietzmann T. The MAPK pathway and HIF-1 are involved in the induction of the human PAI-1 gene expression by insulin in the human hepatoma cell line HepG2. Ann NY Acad Sci 1090 (2006) 355-367
23. Svendsen O.L., Hassager C., Christiansen C., Nielsen J.D., and Winther K. Plasminogen activator inhibitor-1, tissue-type plasminogen activator, and fibrinogen: effect of dieting with or without exercise in overweight postmenopausal women. Arterioscler Thromb Vasc Biol 16 (1996) 381-385
24. Igarashi M., Hirata A., Yamaguchi H., Jimbu Y., and Tominaga M. Pioglitazone reduces atherogenic outcomes in type 2 diabetic patients. J Atheroscler Thromb 15 1 (2008) 34-40
25. Juhan-Vague I., and Alessi M.C. Regulation of fibrinolysis in the development of atherothrombosis: role of adipose tissue. Thromb Haemost 82 (1999) 832-836
26. Targher G., Bertolini L., Rodella S., et al. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring) 16 6 (2008) 1394-1399
27. Targher G., Bertolini L., Scala L., et al. Plasma PAI-1 levels are increased in patients with nonalcoholic steatohepatitis. Diabetes Care 30 5 (2007) e31-e32
28. Joy D., Thava V.R., and Scott B.B. Diagnosis of fatty liver disease: is biopsy necessary?. Eur J Gastroenerol Hepatol 15 (2003) 539-543
29. Mathiesen U.L., Franzen L.E., Aselius H., et al. Increased liver echogenicity in ultrasound reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases. Dig Liver Dis 34 (2002) 516-522